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a b s t r a c t
Atrial ﬁbrillation (AF) is an independent factor increasing the risk of an ischemic stroke (IS)
ﬁvefold. The objective of the study was to evaluate the frequency of coexistence of non-
valvular AF and IS during the acute stroke and to analyze the attitude of AF patients to
treatment.
The study included 3712 successive patients presenting either an IS or a transient
ischemic attack.
The analysis revealed a signiﬁcant increase in the rate of patients with AF and IS in the
years 2010–2013 (31.9%) compared with 2002–2005 (20.2%). A rise in the proportion of AF and
IS patients was recorded over the course of consecutive years in group II. The proportion of
newly detected AF cases during hospital stay differed signiﬁcantly between the groups (16.9%
vs. 31.9%). Group I and II patients differed essentially with regards to hypertension incidence
and female rates. Antiplatelet medications or OACs were taken by a signiﬁcantly greater
number of AF patients in group II. Low number of therapeutic levels of INR was recorded in
both groups.
IS and AF coexist more frequently than indicated by previous assessments and demo-
graphic data from other countries. Increase in the number of IS and AF patients may result
from higher detectability of AF and older age of patients affected with stroke, women in
particular. Despite a well grounded knowledge about the beneﬁts of OACs use in the
prophylaxis of thrombotic-embolic events in AF patients, they are rarely used. A surprisingly
low proportion of patients taking OACs reaches a therapeutic INR level.
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mia and one of the essential modiﬁable ischemic stroke (IS)
risk factors [1]. AF incidence increases with age. Over the last
50 years, due to the population aging the number of AF
patients doubled. AF affects 2–3 patients out of 1000 patients
aged 25–5; 30–40 patients out of 1000 patients aged 55–64, and
50–90 out of 1000 patients aged 62–90. It is estimated that the
disease affects approximately 10% of all past the age of 80 [2].
Currently, there are circa 6 million Europeans suffering from
the disease [3].
With regards to atrial ﬁbrillation etiology, AF is divided into
spontaneous (idiopathic) AF and secondary AF, further
subdivided into valvular and non-valvular [4]. Non-valvular
AF accounts for ca. 50% of all AF cases [5].
AF as a condition predisposing to the development of
arterial embolism seems of particular importance to neurol-
ogists, since as much as 70–90% of all cardiogenic embolisms
affect cerebral arteries [6,7]. AF prevalence places it at the
forefront of cardiogenic causes of stroke [8,9]. According to the
most widely cited studies from Framingham, AF is indepen-
dently associated with a ﬁve-fold elevated risk for stroke [9,10].
AF is diagnosed in 6–26% of IS patients, 8–36% of stroke
patients >80 years of age [11–15]. In a study involving the
Warsaw city population, AF affected 22.8% of stroke patients
hospitalized between 1991 and 1992, and 25% of those
hospitalized in 2005 [16]. In patients above 80, AF is considered
the strongest single IS risk factor [17]. Annual incidence of
stroke in a general population of AF patients is 5% [18]. In
Poland, it is markedly higher than in the Western European
countries [18].
Prognosis in IS in the context of cardiogenic embolism is
typically more serious than in stroke of thrombotic origins.
Stroke developing in AF patients features high rate of
recurrence, more severe course, and higher rate of early
mortality [19,20]. Embolism-caused strokes are more often to
blame for permanent post-stroke disability than thrombotic or
lacunar ones [19–23].
Because of the relationship between AF and IS, the world-
wide interest in the issue and ongoing search for the measures
to prevent embolic complications in AF patients is not
surprising.
Subject literature provides numerous research ﬁndings in
favor of the claim that oral anticoagulant (OAC) prophylaxis in
AF patients is more beneﬁcial than antiplatelet preparation
use [24]. It has been demonstrated that compared with
acetylsalicylic acid (ASA), it signiﬁcantly lowers the risk of IS
in AF patients, only slightly increasing the total risk of a
serious bleeding [18,25]. Despite perfectly substantiated
advantages of OAC prophylaxis, its limited application is still
common.
Taking into consideration the above mentioned wide
discrepancies regarding AF and IS coexistence in epidemio-
logical analyses and single ﬁndings concerning the issue in
Poland, we set off to evaluate the incidence of coexistence of
non-valvular AF and IS, including the ﬁrst detected AF (fd AF)
in the acute stroke, and to analyze the attitude of AF patients to
OAC therapy on the basis of the Szczecin and Szczecin region
patients, assuming that obtained results would be represen-
tative of the overall situation in the country. Furthermore, we
decided to monitor both aspects, particularly the latter, in twotime periods: 2002–2005 and 2010–2013. The former period
corresponds to the early years following the introduction of
the National Program for Stroke Prevention and Treatment in
Poland (year 2000), guidelines on the management of acute
stroke, and the basis for secondary stroke prevention. The
latter refers to the time at which the effects of educational
activities regarding the rules of stroke prevention should be
expected.
1. Materials and methods
The study included 3712 patients with either an IS or a
transient ischemic attack (TIA) hospitalized in the Neurologi-
cal Department of the Pomeranian Medical University (PMU)
in Szczecin between 2002 and 2005 (1525 consecutive patients
– group I) and between 2010 and 2013 (2187 consecutive
patients – group II). The analysis of group I patients was
conducted retrospectively, whereas that of group II was
prospective.
All patients were evaluated with the application of a
specially designed questionnaire listing personal data, data
regarding coexisting conditions, including but not limited to
stroke risk factors, and current treatment, in particular any
antiaggregants and OACs. The use of antiaggregants involved
the taking of ASA, ticlopidine and/or clopidogrel; the use of
OACs – acenocoumarol or warfarin. Information was obtained
directly from the patients and their families and from the
medical records submitted.
All patients underwent neurological examination, a stan-
dard 12-lead electrocardiogram (ECG) and, if necessary, a 24-h
Holter monitoring, Doppler ultrasound of carotid arteries, and
routine laboratory analyses. In addition, the fd AF patients had
an echocardiography performed. Computed tomography (CT)
every time was conducted at admission.
The ‘‘established’’ AF was deﬁned as a paroxysmal,
persistent or permanent AF diagnosed on the basis of repeated
12-lead ECGs and/or the 24-h continuous Holter monitoring
prior to stroke. Fd AF was deﬁned as an AF diagnosed pursuant
to an elective or symptom-dependent standard 12-lead ECG
and/or 24-h Holter monitoring (at admission or during hospital
stay) in patients with no prior AF history.
The grounds for diagnosing arterial hypertension and type
2 diabetes were patient history, medical records and drugs
used. Newly detected arterial hypertension was diagnosed
when at repeated tests the systolic blood pressure (SBP) was
≥140 mmHg and/or the diastolic blood pressure (DBP) was
≥90 mmHg [26]. Newly diagnosed diabetes was determined by
the level of fasting blood glucose after a minimum of 2 test
results ≥126 mg/dl or glucose level ≥200 mg/dl marked at any
time during the day. An alternative criterion for diagnosing
diabetes was a positive result of a glucose tolerance test (blood
glucose ≥200 mg/dl 2 h after oral administration of 75 mg of
glucose) [27].
Valvular and secondary AF patients were excluded from
the study. The exclusion criteria included: hemodynamic
signiﬁcant mitral valve stenosis or an artiﬁcial valve and a
passing AF induced by a reversible clinical condition (ionic
imbalance, myocardial infarction, thyreotoxicosis, pulmo-
nary embolism).
Table 1 – Demographic statistics of AF patients from
group I and II.
Group I Group II p Value
Patients number 316 (20.2%a) 569 (26.01%a) 0.0003
Age 46–93 years
median 76
(SD  9.1)
40–97 years
median 79
(SD  9.6)
0.7638
Sex (female) 57.9% 67.5% 0.0047
Hypertension 74.7% 83.3% 0.0024
Diabetes mellitus 33.2% 29.5% 0.0931
Vascular diseaseb 22.8% 22.3% 0.8739
Stroke/TIA in history 33.2% 28.5% 0.1396
a Per cent of whole group.
b Peripheral artery disease, carotid artery disease, myocardial
infarct.
Table 2 – First detected AF in first ever stroke
patients – comparison between consecutive years of
group II (n = 439 individuals).
2010 29.3%a
p = 0.2051
2011 37.6%
p = 0.1031
2012 28.2%
p = 0.5155
2013 32.5%
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The majority of the distributions of the analyzed continuous
variables was signiﬁcantly different from the normal distribu-
tion pattern (Shapiro–Wilk test); thus, analyses were per-
formed with the application of non-parametric tests. To assess
the signiﬁcance of the differences in variables between the two
examined patient groups the following tests were conducted:
the Kruskal–Wallis test, the Mann–Whitney U test, and the chi-
square test. Logical regression was applied to the multivariate
analysis of the odds ratio (OR) at 95% conﬁdence interval
(95% CI). Statistical signiﬁcance was set at p < 0.05. Calcula-
tions were performed with the use of STATISTICA ver. 10.1.
3. Results
The analysis revealed a signiﬁcant increase in the rate of
patients with AF and IS in the years 2010–2103 compared with
2002–2005 (group II – 31.9%, group I – 20.2% respectively,
p = 0.0003). No statistically signiﬁcant difference was observed
in the proportion of patients with paroxysmal and permanent
AF between the groups (group I: 39% paroxysmal, 62%
permanent, group II: 34% paroxysmal, 67% permanent,
p = 0.1588). A rise in the proportion of AF and IS patients was
recorded over the course of consecutive years in group II. A
signiﬁcant increase was recorded between the year 2010 and
2011 (p = 0.0031). In the year 2012, the proportion was similar to
that of the year before. In 2013, in turn, it was higher than in
2012. The most marked difference was observed between the
years 2010 and 2013 (p = 0.0004). However, there were no
differences between the rate of patients with AF and TIA in
consecutive years in group II (Fig. 1).
Demographic data of AF and IS patients in both groups are
presented in Table 1. It shows that the patients differed
essentially with regards to arterial hypertension incidence and
female rates.
Based on Table 2 data, the proportion of the newly detected
AF cases during hospitalization due to a ﬁrst-time stroke did not
differ signiﬁcantly over following years in group II. However, it
was signiﬁcantly lower in group I (16.9%). The number of AF
patients taking antiplatelets or OACs was signiﬁcantly higher in
group II. Still, in spite of extensive knowledge about arrhythmia,
prior to stroke OACs were used by a relatively small proportion
of patients in both groups: 10.2 and 18.3% respectively (group IFig. 1 – Per cent of AF patients in regard to whole group I and
consecutive years of group II.vs. II, p = 0.0066); antiaggregants were taken by 36.7 and 46.6%,
respectively (group I vs. II, p = 0.0071).
Looking at the INR values in patients with AF established
prior to stroke, we found that the proportion of patients with
the ratio of 2.0–3.0 or >3.0 (which meant they were taking a
drug) was signiﬁcantly low (Fig. 2).
4. Discussion
IS and AF coexistence estimate is highly varied and, depending
on the source, it may affect between 6 and over 30% of IS patients
[12,14,16,28]. In a multicenter study evaluating factors inﬂuenc-
ing delayed onset of thrombotic treatment in IS conducted in the
Central and Eastern European countries, including Poland, AF
was recorded in 25% of patients [29]. Other studies involving a
Polish group of IS patients revealed that AF affected between
23.6 and 30.1% of patients [30–32]. In a study of Caucasian
population evaluating the dependency between renal failureFig. 2 – International Normalized Ratio (INR) in group II
patients with AF history prior to stroke.
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as much as 36.4% of study participants [33].
Our ﬁndings indicate a signiﬁcant increase in the number of
patients with AF and IS in the years 2010–2013 compared with
2002–2005. The proportion of patients in 2013 was as high as
35%. Nevertheless, we are unable to state what is the explicit
cause of such signiﬁcant increase in the ratio of AF and IS
patients over the last years. Several factors might have
contributed to this result. Above all, a rise in AF detectability
both preceding and during the hospital stay. Furthermore,
group II patients were older (though, not signiﬁcantly) and
thus they more often had arterial hypertension than group I
patients (perhaps, they were more often diagnosed with one).
Women with a higher risk of AF-associated stroke predomi-
nated group II [34]. However, no differences were found
between the rate of patients with paroxysmal and permanent
AF and TIA between the groups or in group II over the
consecutive years. Presumably, such a low, ﬁxed proportion of
AF and TIA patients is consequential to permanent underesti-
mation of coexistence of both pathologies since TIA patients'
hospital stay is typically short, which often does not allow for
passing AF episodes to be identiﬁed.
Due to a frequently asymptomatic course of AF, stroke
happens to be the ﬁrst complication of the arrhythmia [35]. It
has been demonstrated that the longer the time of electrocar-
diographic monitoring of patients in the acute IS phase, the
better the chance of detecting AF. The ratio of fd AF patients in
the acute IS phase rises from just a few percent [35–39] up to
more than 30% [40–42]. Gladstone et al. [43] proved that a
prolonged ECG monitoring (up to 30 days) in patients after
stroke/TIA found initially to be cryptogenic, increases the
detectability of paroxysmal AF ﬁvefold compared to standard
monitoring. This conﬁrms the need to introduce an extended
ECG monitoring in order to properly establish etiology and
implement suitable secondary preventive measures [44,45].
In our study, the proportion of fd AF in the years 2010–2013
reached 37.6% (year 2011). This result is based on a routine 24-h
Holter monitoring. The above indicates that a globally
signiﬁcant increase in IS and AF coexistence in our patients
in the years 2010–2013, may be, at least partially, attributed to
higher AF detectability at stroke.
New guidelines considerably extended the range of
patients that should be administered a long-term OAC
therapy. Only a male under the age of 64 with the so-called
isolated, focal, paroxysmal AF and no additional risk factors of
developing thrombotic-embolic incidents, may renounce
antithrombotic treatment [46–48], although this may be
subject to further considerations due to dangerous effects of
any potential stroke.
Studies conducted more than 10 years ago demonstrated
that in 2002 56% of Americans with AF took OACs [49]. A similar
Spanish comparison showed that the ratio of patients taking
OACs was almost 30% and antiaggregants – 46%. Nevertheless,
we need to stress that despite greater awareness of AF-induced
thrombo-embolic risks, the proportion of patients taking OAC is
still not optimal. Even ﬁndings from the year 2013 indicate that it
is ca. 50%, or below [46,50].
The number of AF patients in our study taking antiplatelets
or OACs was signiﬁcantly higher in group II, but despite the
fact that arrhythmia was known to be one of the stroke riskfactors, OACs were used by a relatively small proportion of
patients in both groups prior to stroke: 10.2 and 18.3%
respectively. The proportion is at least two- or even 3-times
lower than in other comparisons [44,49,50]. If we assumed that
AF patients using antiaggregants proﬁted to some extent, the
proportion of such patients would still prove insufﬁcient, as
the numbers were 36.7% of the patients in group I and 46.6% of
the patients in group II.
The underrated issue here is the efﬁcacy of the drugs
administered measured by the therapeutic index. Research
shows that at most half of the patients taking OACs achieves a
therapeutic value of INR (it is possible that it is a mere 20% of
the patients) [42]. Considering INR values established prior to
stroke in our AF patients admitted to the Department due to
stroke, the proportion of patients with a 2.0–3.0 index value or
>3.0 (which meant they were taking a drug) was signiﬁcantly
low (barely 9%). This result is particularly striking when
compared with the above cited estimates from other studies,
where a half of AF patients receiving treatment represented
the therapeutic range of OACs. It is largely attributed to the
difﬁculties in maintaining INR in the narrow therapeutic
window. Even in patients treated with OACs and attaining INR
value of 2.0–3.0 at testing, the total therapeutic time most
probably does not exceed 50% of the therapy period [42,46]. In
the light of these data, the meaning of our result (9% of the
patients) becomes even more negative.
An alternative to VKA and, presumably, the future in IS
prevention in AF patients, are novel OACs featuring stable
pharmacokinetics, lack of major interactions with other drugs
or foods inﬂuencing the activity of P450 cytochrome enzymes
and, what is essential, not requiring the monitoring of
circulation system parameters. Said drugs are becoming more
and more widely used in Poland.
Above-described considerations on the AF and stroke,
regarding the pathogenesis and treatment of cerebro-vascular
events, justify need creating close cooperation with cardiologic
teams in searching for AF in every patient with embolic stroke
of uncertain source (ESUS).
5. Conclusions
1 Ischemic stroke and atrial ﬁbrillation in the study popula-
tion coexist more often than indicated by previous estimates
and demographic data from other countries.
2 Amongst the causes of the increase in the number of
patients with stroke and atrial ﬁbrillation may be higher
detectability of atrial ﬁbrillation preceding and, most
importantly, during hospital stay, and older age of patients
affected with a stroke, women in particular.
3 Despite well substantiated knowledge about the beneﬁts of
antithrombotic drug use in the prevention of thromboem-
bolic events in patients with atrial ﬁbrillation, they are used
rarely. In addition, a surprisingly low proportion of patients
taking antithrombotic drugs reaches the target INR level.
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